Your browser doesn't support javascript.
loading
Outcomes of patients with Wilms' tumour stage III due to positive resection margins only: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies.
Vujanic, Gordan M; Graf, Norbert; D'Hooghe, Ellen; Chowdhury, Tanzina; Vokuhl, Christian; Al-Saadi, Reem; Pritchard-Jones, Kathy; Melchior, Patrick; Furtwängler, Rhoikos.
  • Vujanic GM; Department of Pathology, Sidra Medicine, Doha, Qatar.
  • Graf N; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine - Qatar, Doha, Qatar.
  • D'Hooghe E; Department of Paediatric Haematology and Oncology, Saarland University Hospital, Homburg, Germany.
  • Chowdhury T; Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Vokuhl C; Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Al-Saadi R; Department of Pathology, Division of Paidopathology, University of Bonn, Bonn, Germany.
  • Pritchard-Jones K; Departmental Biology and Cancer Programme, UCL Great Ormond Street of Child Health, University College London, London, UK.
  • Melchior P; Histopathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Furtwängler R; Departmental Biology and Cancer Programme, UCL Great Ormond Street of Child Health, University College London, London, UK.
Int J Cancer ; 152(8): 1640-1647, 2023 04 15.
Article en En | MEDLINE | ID: mdl-36444500
ABSTRACT
Stage III Wilms' tumour (WT) represents a heterogeneous group which includes different criteria, but all stage III patients are treated according to the same study regiment. The aim of the study was to retrospectively analyse outcomes in patients with stage III due to positive resection margins (RM) only, sub-grouped in RM with viable (RM-v) and nonviable (RM-nv) tumour. Patients were treated pre- and postoperatively according to the SIOP-WT-2001 protocol in the UK-CCLG and GPOH WT trials and studies (2001-2020). There were 197 patients, including 134 with localised, abdominal stage III and 63 with overall stage IV, but abdominal stage III. Stage III due to RM-v had 126 patients, and due to RM-nv 71 patients. The overall 5-year local-relapse-free survival (RFS), event-free (EFS) and overall survival (OS) estimates for all patients with abdominal stage III RM were 95.7% (±SE1.5%), 85.1 (±SE2.6%) and 90.3% (±SE2.2%), respectively. Patients with stage III RM-nv had significantly better RFS and EFS than patients with RM-v (P = .027 and P = .003, respectively). A multivariate analysis showed that RM-v remained a significant factor for EFS when adjusted for age, presence of metastasis at diagnosis, histological risk group and overall stage in Cox regression analysis (P = .006). Patients with stage III due to RM-nv only exhibited no local recurrence and have a significantly better RFS and EFS than patients with RM-v. The results suggest that exclusion of RM-nv as a stage III criterion in the UMBRELLA staging system and consequent treatment reduction is warranted.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tumor de Wilms / Neoplasias Renales Tipo de estudio: Guideline Límite: Humans / Infant País como asunto: Europa Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tumor de Wilms / Neoplasias Renales Tipo de estudio: Guideline Límite: Humans / Infant País como asunto: Europa Idioma: En Año: 2023 Tipo del documento: Article